Among the 28 patients with GC/GEJ cancer, 25 (89.3%) had received at least two lines of therapy or at least a triple combination of fluoropyrimidine, oxaliplatin and paclitaxel, and 12 (42.9%) had received prior anti-PD-1/PD-L1 antibody therapy. The gene discussed is CD274; the disease is gastric cancer.